Conference call and webcast to be held at
4:30 p.m. ET
NEW
HAVEN, Conn., March 13,
2024 /PRNewswire/ -- Trevi
Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for patients
with chronic cough in idiopathic pulmonary fibrosis (IPF) and
refractory chronic cough (RCC), today announced that senior
management will host a conference call and live audio webcast
on Wednesday, March 20, 2024, at 4:30 p.m. ET, to provide
a corporate update and review the Company's financial results for
the quarter and year ended December 31, 2023.
To participate in the live conference call by phone, please dial
(888) 317 6003 (domestic) or (412) 317 6061 (international) and
provide access code 4401006. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.TreviTherapeutics.com. An archived replay of
the webcast will also be available for 30 days on the Company's
website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for patients with chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi
also is evaluating Haduvio for prurigo nodularis. Haduvio is a dual
ĸ-opioid receptor agonist and µ-opioid receptor antagonist that
works both centrally in the brain as well as peripherally in the
lungs and has the potential for a synergistic antitussive effect to
treat chronic cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal relief to patients. RCC affects up to 10% of the adult
population, and Haduvio's expansion into RCC has the potential to
reach patients suffering from moderate to severe chronic cough.
There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the U.S. Drug
Enforcement Agency. Trevi intends to propose Haduvio as the trade
name for oral nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q4-and-year-end-2023-financial-results-and-provide-a-corporate-update-on-march-20-2024-302086846.html
SOURCE Trevi Therapeutics, Inc.
